XML 53 R33.htm IDEA: XBRL DOCUMENT v3.25.1

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):

			Year Ended December 31,
			2024						2023						2022
Total revenue (a)			$	149,962					$	58,749					$	151,941
Cost of product sales			847						619						3,351
Cost of manufacturing sales			11,452						7,603						4,033
Research and development expenses:
Vobramitamab duocarmazine			39,809						39,217						55,381
Lorigerlimab			36,805						27,716						21,581
MGC028			24,055						14,408						—
Preclinical antibody-drug conjugates (ADCs)			18,102						11,170						12,975
MGC026			14,126						13,523						5,287
Margetuximab			10,846						16,081						26,869
MGD024			9,734						6,974						7,857
Next-generation T-cell engagers			8,421						10,464						13,335
Retifanlimab			2,129						3,452						2,156
Enoblituzumab			1,906						5,344						14,725
Other programs			11,261						18,234						46,860
Total research and development expenses			177,194						166,583						207,026
Selling, general and administrative expenses			71,047						52,188						58,949
Other segment income, net (b)			43,612						159,186						1,660
Net loss			$	(66,966)					$	(9,058)					$	(119,758)

(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.

(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration